Results 191 to 200 of about 193,702 (280)

Long-term survival after ALK-TKI resistance through immunotherapy combined with chemotherapy in ALK-positive non-small cell lung cancer: a case report. [PDF]

Front Oncol
Fu C, Yang L, Qiao H, Liu X, Wang J.
europepmc   +1 more source

Early Introduction and Other Characteristics in Children With Suspected Severe Peanut or Tree Nut Allergy: Finnish Cohort

Acta Paediatrica, EarlyView.
ABSTRACT Aim Peanut and tree nut allergies are leading causes of food‐induced anaphylaxis in children. We aimed to examine early introduction and allergic characteristics in children with suspected severe peanut and/or tree nut allergy. Methods Children aged 3–16 years with suspected severe peanut and/or tree nut allergy were recruited from Tampere ...
Emilja Särkkä, Lasse Saarimäki, Jennifer L. P. Protudjer, Iida Ojaniemi, Jussi Karjalainen, Heini Huhtala, Sandra Ekström, Inger Kull, Juho E. Kivistö   +8 more
wiley   +1 more source

An Autochthonous Model of Lung Cancer Identifies Requirements for Cellular Transformation in the Naked Mole Rat. [PDF]

Cancer Discov
Shepard A, Lester DK, Troutman S, Hoxha S, Khaled WT, Smith ESJ, Park TJ, Buffenstein R, Du D, Teng M, Dengler-Crish CM, Tsai KY, Flores ER, Ventura A, Kissil JL.   +14 more
europepmc   +1 more source

Association of immune relevant single nucleotide polymorphisms with ALK-positive anaplastic large cell lymphoma presentation and outcome: results of the immuno ALCL study. [PDF]

J Transl Med
Adriana P, Carbonnier V, De Palma FDE, Perez-Lanzon M, Vergé V, Quivoron C, Lamant L, Brugieres L, Rigaud C, Ducassou S, Dourthe ME, Le Deley MC, Damm-Welk C, Woessmann W, Minard-Colin V, Maiuri MC, Kroemer G.   +16 more
europepmc   +1 more source

ALK Positive [PDF]

, 2020
openaire   +1 more source

Atezolizumab + Chemotherapy for Advanced Non‐Small Cell Lung Cancer in Japanese Clinical Practice (J‐TAIL‐2)

Cancer Science, EarlyView.
The J‐TAIL‐2 prospective, observational study evaluated atezolizumab combined with several chemotherapy regimens in patients with advanced/metastatic non‐small cell lung cancer in routine clinical practice in Japan. The real‐world efficacy and safety of each atezolizumab combination were found to be comparable to those seen in the relevant global ...
Hiroshige Yoshioka, Makoto Nishio, Kadoaki Ohashi, Atsushi Osoegawa, Eiki Kikuchi, Hideharu Kimura, Yasushi Goto, Junichi Shimizu, Eisaku Miyauchi, Ichiro Yoshino, Toshihiro Misumi, Yasutaka Watanabe, Akito Hata, Akira Kisohara, Shoichi Kuyama, Masafumi Yamaguchi, Asako Miwa, Shunichiro Iwasawa, Misa Tanaka, Akihiko Gemma   +19 more
wiley   +1 more source

ALK-Targeted Therapy: Resistance Mechanisms and Emerging Precision Strategies. [PDF]

Curr Issues Mol Biol
Zhang YK, Tong JB, Luo MX, Qin ZP, Wang R.   +4 more
europepmc   +1 more source

PSMD12 Overexpression Promotes Lung Adenocarcinoma Progression via Ubiquitin–Proteasome Pathway Dysregulation

Cancer Science, EarlyView.
PSMD12, located on the frequently amplified 17q region in LUAD, is upregulated in tumors and associated with poor prognosis and advanced stage. Functional studies revealed that PSMD12 promotes cell proliferation and G2/M transition by inhibiting CDK1 ubiquitination and stabilizing CDK1.
Yuya Ono, Hajime Otsu, Takaaki Masuda, Keisuke Kosai, Shohei Shibuta, Kosuke Hirose, Takashi Ofuchi, Yuki Ando, Koto Kawata, Yasuo Tsuda, Yusuke Yonemura, Taro Tobo, Tomoyoshi Takenaka, Tomoharu Yoshizumi, Koshi Mimori   +14 more
wiley   +1 more source

Correction: Detection of EML4-ALK in Lung Adenocarcinoma Using Pleural Effusion with FISH, IHC, and RT-PCR Methods. [PDF]

PLoS One
PLOS One Editors.
europepmc   +1 more source

IMpower010: 5‐Year Outcomes of Atezolizumab in Japanese Patients With Resected Stage IB–IIIA Non‐Small Cell Lung Cancer

Cancer Science, EarlyView.
The global Phase 3 IMpower010 study (NCT02486718) evaluated atezolizumab versus best supportive care (BSC) after complete resection and adjuvant platinum‐based chemotherapy in patients with stage IB–IIIA non‐small cell lung cancer (NSCLC). Here, we report updated efficacy and safety results from the disease‐free survival (DFS) final and overall ...
Morihito Okada, Shunichi Sugawara, Yasutaka Watanabe, Haruhiro Saito, Toyofumi F. Chen‐Yoshikawa, Yasushi Goto, Wataru Nishio, Shizuka Nakagawa, Morihiko Hayashi, Hirotsugu Kenmotsu   +9 more
wiley   +1 more source